Innovative Pilot Program Enhances Cancer Care and Support for Indigenous Communities

A pilot program by the University of Oklahoma enhances cancer care access and support for Indigenous communities, aiming to reduce disparities and improve health outcomes through innovative care coordination.
Researchers from the University of Oklahoma have developed and tested a new care coordination program aimed at improving access to cancer treatment for Indigenous populations. Indigenous residents in Oklahoma experience significantly higher cancer mortality rates—44% higher than the general population within the state and 67% higher nationwide—highlighting urgent disparities in healthcare access and outcomes. While many Indigenous patients receive primary care at Indian Health Service and tribal health facilities, they often face challenges such as delays, costs, and complex referral processes when seeking specialized cancer care outside their primary facilities.
Amanda Janitz, Ph.D., MPH, an epidemiology associate professor at OU, emphasized that the current referral system can be confusing and time-consuming, often leading to delays that negatively impact patient health. Additionally, long travel distances and associated costs can be formidable barriers.
Since 2012, the OU Health Stephenson Cancer Center’s American Indian Navigation Program has supported over 4,400 Indigenous patients across 65 tribes, offering logistical assistance and emotional support. Building on this success, a recent pilot project, involving 128 patients between July 2023 and February 2025, aimed to further improve care through targeted interventions. This included a reduction in missed appointments from 19% to 11%, an increase in depression screening to 100%, and providing financial aid for transportation and lodging. Patients also gained a better understanding of clinical trials, while healthcare providers received cultural competency training.
The center is now expanding this initiative with the Care Coordination and Communication Program in Oncology for Tribal Health Systems. A key component involves virtual "huddles" where teams from the Stephenson Cancer Center and referring facilities collaborate in real-time to discuss patient cases, barriers, and treatment plans. These meetings include clinicians, American Indian navigators, and case managers addressing psychosocial and logistical issues. This team approach aims to streamline communication, reduce delays, and improve outcomes.
Participants in the program will be randomly assigned to receive either the huddle-based coordination or standard navigation services, with all receiving enhanced services later. The goal is to evaluate whether this approach accelerates diagnosis, treatment initiation, and improves patient satisfaction, ultimately contributing to better survival rates and health outcomes.
This innovative approach demonstrates a promising pathway toward reducing healthcare disparities faced by Indigenous communities and could serve as a model for broader implementation.
source: https://medicalxpress.com/news/2025-09-cancer-access-indigenous-communities.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Artificial Intelligence Predictions on Long-Term Concussions in Student Athletes
University of Michigan researchers utilize AI to predict long-term health impacts of concussions on college athletes, emphasizing early assessments over injury frequency.
UK Court Dismisses Pfizer and BioNTech's Appeal in COVID-19 Patent Dispute
Pfizer and BioNTech face a legal setback as the UK Court of Appeal upholds a patent ruling favoring Moderna in their ongoing COVID-19 vaccine patent dispute. The decision has major implications for biotech patent rights and vaccine development.
Understanding the Latest Developments in the COVID-19 Vaccine Policies
Stay informed on the latest updates and controversies surrounding COVID-19 vaccine eligibility and policies in 2025, as states and federal agencies navigate a rapidly changing landscape.
Largest Phase III Clinical Trial Demonstrates Promising Results for New Hypertension Treatment
The Launch-HTN trial reveals that lorundrostat, an aldosterone synthase inhibitor, effectively lowers blood pressure in resistant hypertension with a strong safety profile, marking a milestone in cardiovascular research.



